Cross-ListedKalshi42%Poly45%Δ3pts▲1.8%Will the FDA approve a new obesity drug (beyond Wegovy/Mounjaro class) in 2026?Markets price 42% odds. Next catalyst: FDA Advisory Committee Meeting.$1.7M volumeExpires Dec 31Mar 15